Innate Pharma (OTCMKTS:IPHYF) Shares Down 1.9%
Innate Pharma SA (OTCMKTS:IPHYF)’s share price fell 1.9% on Friday . The stock traded as low as $7.49 and last traded at $7.50, 200 shares traded hands during mid-day trading. A decline of 78% from the average session volume of 913 shares. The stock had previously closed at $7.64.
Several research firms have weighed in on IPHYF. Zacks Investment Research downgraded shares of Innate Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. ValuEngine raised shares of Innate Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, October 24th.
The business’s 50-day simple moving average is $6.74 and its 200-day simple moving average is $6.64. The stock has a market cap of $440.07 million, a PE ratio of 124.92 and a beta of -0.23.
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Further Reading: Quiet Period
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.